This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH
A cyclical bottom (maybe?), a special situation, and a consolidating industry leader mark the long side.
LSXMB ZDGE BATRK FWONB LSXMA GNE.PRA PANW BATRR RTTR FNF GNE FWONA DRQ BILI MAT STC FNFV RFL FWONK FAF BATRB LSXMK RFL.WI BATRA
Fidelity National Financial (FNF) is the largest title insurer in the United States. There are several reasons why I think title insurers are a great way to participate in home price appreciation over the next decade. First, banks require title insurance for mortgage transactions, so customers are essentially captive. Second, due to price regulations and a consolidated industry, there is very little price competition.
STC TRV FNFV MET FAF BKI FNF
Thank you for standing by and welcome to the FNF 2018 First Quarter Earnings Call. All participants are in a listen-only mode. Later, there'll be an opportunity for questions. As a reminder, this call is being recorded and will be available for replay after 3:30 PM today through May 10. You may access the replay by dialing 1-800-475-6701 or 320-365-3844 and enter access code 447137.
Includes detailed analysis of Oakmark Equity And Income Fund's positions in APC, CSL, CMCSA, LBRDA, LBRDK, CLGX, QRVO, REGN.
C.WSA CVS HCA GM.WS.A GM.WS.B GM.WS.C BKFS CMCSK BAC REGN BHGE ARNC BKI CGBBW MTW GM.WSB AEUA APC PM PFG CCV TEL CCZ FNF BAC C.WS.B CHTR CLGX FNFV C.WS.A C.PRP C.PRU GM C.PRS LBRDB QRVO C C.PRL C.PRJ CMCSA C.PRK CSL MA C.PRG LBRDK C.PRC BHI C.PRPCL CCV.CL JLL LBRDA UNH
Greenlight Capital's (GLRE) new innovation unit, Greenlight Re, is expected to amp up its efficiency and quality of products and services available to its clients.
ATHTF AGO.PRE AGO.PRF AGO.PRB RYAM.PRA FNF CHSP AJRD FNFV NYLD ACRE AGO POWL NYLD.A CHSP.PRA RYAM SJI SVU TACO ANTM MYE NMIH TACOW DHIL ANTX
Arthur J. Gallagher & Co. (AJG - Free Report) has purchased Integrity Transportation Insurance Agency, LLC to solidify its foothold in the South Central region of the United States with regard to transportation business. However, financial details of the transaction have been kept under wraps. Details of the Transaction Houston, TX-based Integrity Transportation operates as a retail property/casualty broker, catering to Texas-based transportation clients, mainly long-haul truckers.
STC FNFV XL XLGLF FNF
White Mountains Insurance Group, Ltd. (WTM - Free Report) has agreed to acquire a majority equity stake in NSM Insurance Group for $388 million. The transaction is expected to culminate by the second quarter of 2018, subject to closing conditions. Rationale Behind the Transaction NSM Insurance Group, a leading specialty insurance program administrator, placing in excess of $500 million in premiums.
STC NXT FNFV XL XLGLF WTM FNF
Arthur J. Gallagher & Co. (AJG - Free Report) has purchased McGregor & Associates to strengthen its risk management potential in the southern region of California. This move in turn will likely fortify the company’s already robust inorganic growth portfolio. However, financial details of the transaction have been kept under wraps. Details of the Transaction Established in 1993, McGregor & Associates operates as a health benefits administrator and offers services to both private and public sector clients across the Californian state.
STC FNFV XL XLGLF FNF
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
6h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET